Sustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain

Table 1

Characteristics of ITP patients treated with romiplostim.

Case number	ITP classification	ITP	Baseline platelet count	Previous ITP treatments	Initial romiplostim dose	Time to response (platelet count)	Time to romiplostim taper	Time to romiplostim discontinuation	Sustained response
1	Newly diagnosed	5 weeks	20 10^9/L	2 (IVIG, prednisone)	3 µg/Kg	2 weeks (270 10^9/L)	52 weeks	16 months	Yes
2	Persistent	13 weeks	1 10^9/L	2 (IVIG, dexamethasone)	3 µg/Kg	1 week (649 10^9/L)	1 week	14 weeks	Yes
3	Chronic; splenectomized	58 months	2 10^9/L	3 (IVIG, dexamethasone, splenectomy)	3 µg/Kg	2 weeks (378 10^9/L)	52 weeks	18 months	Yes
4	Chronic; nonsplenectomized	180 months	6 10^9/L	4 (prednisone, rituximab, dexamethasone, eltrombopag)	3 µg/Kg	2 weeks (65 10^9/L)	11 weeks	19 weeks	Yes

the start of romiplostim treatment. defined as platelet count ≥50 10⁹/L. from romiplostim onset. as platelet count ≥50 10⁹/L for 24 consecutive weeks in the absence of any treatment for ITP. ITP: primary immune thrombocytopenia; IVIG: intravenous immunoglobulin.